Skip to main content
. Author manuscript; available in PMC: 2010 Oct 25.
Published in final edited form as: N Engl J Med. 2008 Oct 15;359(19):1995–2004. doi: 10.1056/NEJMoa0804525

Figure 4. Hazard Ratios for Poor Survival and Late Recurrence in Selected Subgroups of Patients in the Validation Set.

Figure 4

The hazard ratio was for poor survival among patients with the poor-prognosis gene signature (Panel A) or for late recurrence among patients with the late-recurrence gene signature (Panel B), as compared with those without the signature. BCLC denotes Barcelona Clinic Liver Cancer staging system, which ranks hepatocellular carcinoma in five stages, ranging from 0 (very early stage) to D (terminal stage). Data are missing for one patient in Panel B.